Artificial intelligence promises to shake up virtually every sector and industry. There are few applications it could be used for as important as human health – it is quite literally a matter of life and death.
However, the pharmaceutical industry is not known as a bastion of openness or innovation. The process of drug discovery has largely remained unchanged for decades. One company hopes to change this, dramatically accelerating the process using AI: BenevolentBio, a subsidiary of BenevolentAI. Techworld spoke to CEO Dr Jackie Hunter.
© LS:N Global
What is BenevolentAI’s main mission?
BenevolentAI’s mission is to apply its AI technology to accelerate scientific discovery and address some of humanities’ most pressing challenges, with human health being a starting point.
Healthcare is an area where applied AI can have a tremendous effect, helping to revolutionise the drug discovery process by creating a new scientific method, one led by technology. Currently the process is hugely
To read more see the full post at: BenevolentAI Q&A: Techworld meets Dr Jackie Hunter, CEO of BenevolentBio - Techworld.com